An mRNA influenza vaccine bests an inactivated quadrivalent flu vaccine against two different strains in phase 3 study.

Influenza prevention with the cell-based quadrivalent vaccine (QIVc) was superior to the egg-based vaccine (QIVe) during the US 2022–2023 flu season.

A quadrivalent nucleoside-modified messenger RNA influenza vaccine met superiority criteria compared with a licensed inactivated vaccine.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of infections, said Kelly Lindert, MD, vice president of clinical research and ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Robert F. Kennedy Jr.’s top vaccine adviser has compared vaccines to hot dogs while challenging the former heads of the Centers for Disease Control and Prevention to a scientific debate. Three months ...